Stocks · News reference
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share